Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
DRUG Stock Chart & Stats
$53.94
$0.82(2.04%)
At close: 4:00 PM EST
$53.94
$0.82(2.04%)
Day’s Range― - ―
52-Week Range$23.18 - $70.23
Previous Close$40.4
Volume34.65K
Average Volume (3M)102.09K
Market Cap
C$437.35M
Enterprise Value$204.27M
Total Cash (Recent Filing)C$51.39M
Total Debt (Recent Filing)C$141.03K
Price to Earnings (P/E)―
Beta3.50
Next Earnings
Dec 18, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding7,084,639
10 Day Avg. Volume115,326
30 Day Avg. Volume102,086
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$78.24Price Target Upside45.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DevelopmentThe Phase 2 BREAKTHROUGH trial for BMB-101 in absence epilepsy and developmental and epileptic encephalopathies remains on track to deliver top-line data, potentially de-risking the program and paving the way for advancement to Phase 3.
Drug Design And EfficacyBMB-101's unique design as a G-protein–biased 5-HT agonist is engineered to sustain efficacy and reduce the risk of tolerance compared with legacy serotonergic drugs.
Market OpportunitiesAbsence seizures represent a blockbuster opportunity with about 75,000 patients in the US having forms of epilepsy where absence seizures predominate, and are poorly served by approved medications.
Bears Say
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $23.18 and its highest was $70.23 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is C$437.35M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Dec 18, 2025 which is in 48 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.531 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.039.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -0.56.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 7,084,639 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.531 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went up 4.92%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
Bright Minds Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$78.24 (45.04% Upside)
C$78.24 (45.04% Upside)
Blogger Sentiment
Bullish
DRUG Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
145.60%
12-Months-Change
Fundamentals
Return on Equity
-30.79%
Trailing 12-Months
Asset Growth
736.23%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
$78.24
▲(45.04% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
NervGen Pharma
―
Eupraxia Pharmaceuticals
―
Ownership Overview
30.80% Insiders
1.07% Mutual Funds
44.23% Other Institutional Investors
20.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---